Electrochemical biosensor for simultaneously detection of Tamoxifen
Abstract
Cancer is described as the uncontrollably multiplying abnormal proliferation of cells. Cancer can affect everyone, and risk of which rises with age, lifestyle, and environmental toxins. Tamoxi̇fen (TAM) which is a selective estrogen receptor modulator, has estrogenic or antiestrogenic effects on the breast tissue by binding to the estrogen receptors. The current study presents a voltammetric biosensor to identify the effect of Tamoxifen on DNA structure. In this study, the effect of TAM on the double-stranded DNA (dsDNA) was investigated electrochemically in both the presence and absence of antioxidants. For this purpose, TAM-dsDNA-antioxidant interaction investigated by using the pencil graphite electrode (PGE). The DNA modified sensor was created simply by wet-adsorbtion method. The prepared biosensor was examined electrochemically by square wave voltammety (SWV) method, and its lowest concentration and optimum pH range were determined. The effect of TAM on dsDNA was investigated simultaneously for the first time in the literature.
Keywords
References
- [1]. M. Clemons, S. Danson, and A. Howell, “Tamoxifen ('Nolvadex’): A review,” Cancer Treat. Rev., vol. 28, no. 4, pp. 165–180, 2002, doi: 10.1016/S0305-7372(02)00036-1.
- [2]. D. J. Bentrem and V. Craig Jordan, “Tamoxifen, raloxifene and the prevention of breast cancer.,” Minerva Endocrinol., vol. 27, no. 2, pp. 127–139, 2002, doi: 10.1210/edrv.20.3.0368.
- [3]. S. Mandlekar and A. N. T. Kong, “Mechanisms of tamoxifen-induced apoptosis,” Apoptosis, vol. 6, no. 6, pp. 469–477, 2001, doi: 10.1023/A:1012437607881.
- [4]. M. Fouladgar, H. Karimi-Maleh, F. Opoku, and P. P. Govender, “Electrochemical anticancer drug sensor for determination of raloxifene in the presence of tamoxifen using graphene-CuO-polypyrrole nanocomposite structure modified pencil graphite electrode: Theoretical and experimental investigation,” J. Mol. Liq., vol. 311, p. 113314, 2020, doi: 10.1016/j.molliq.2020.113314.
- [5]. I. Girault, I. Bièche, and R. Lidereau, “Role of estrogen receptor α transcriptional coregulators in tamoxifen resistance in breast cancer,” Maturitas, vol. 54, no. 4, pp. 342–351, 2006, doi: 10.1016/j.maturitas.2006.06.003.
- [6]. M. M. T. Buckley and K. L. Goa, “Tamoxifen: A Reappraisal of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use,” Drugs, vol. 37, no. 4, pp. 451–490, 1989, doi: 10.2165/00003495-198937040- 00004.
- [7]. B. J. A. Furr and V. C. Jordan, “The pharmacology and clinical uses of tamoxifen,” Pharmacol. Ther., vol. 25, no. 2, pp. 127–205, 1984, doi: 10.1016/0163-7258(84)90043-3.
- [8]. K. Lee, B. A. Ward, Z. Desta, D. A. Flockhart, and D. R. Jones, “Q uantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection : application to a clinical trial,” vol. 791, pp. 245–253, 2003.
- [9]. X. Liu, J. Zhang, J. Yin, and H. Duan, “Analysis of hormone antagonists in clinical and municipal wastewater by isotopic dilution liquid chromatography tandem mass spectrometry,” pp. 2977–2985, 2010, doi: 10.1007/s00216-010-3531-0.
- [10]. S. Xiao, Y. Yang, J. Zhang, Y. Wu, and B. Shao, “[Determination of 6 antiestrogens in fish tissues by ultra performance liquid chromatography-tandem mass spectrometry],” Se pu = Chinese J. Chromatogr., vol. 29, no. 11, p. 1055—1061, 2011, [Online]. Available: http://europepmc.org/abstract/MED/22393691.